BAY 2395840
/ Bayer, Evotec
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
November 13, 2023
A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain
(clinicaltrials.gov)
- P2 | N=80 | Completed | Sponsor: Bayer | Phase classification: P2a ➔ P2
Phase classification • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain
April 19, 2023
A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Bayer | N=20 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Diabetic Neuropathy • Neuralgia • Pain • Renal Disease
March 15, 2023
A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: Bayer | Recruiting ➔ Completed | N=36 ➔ 24
Enrollment change • Trial completion • Diabetic Neuropathy • Neuralgia • Pain
December 15, 2022
A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain
(clinicaltrials.gov)
- P2a | N=80 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed
Trial completion • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain
November 08, 2022
A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Bayer | Trial completion date: Jul 2023 ➔ Oct 2023 | Initiation date: Nov 2022 ➔ Mar 2023 | Trial primary completion date: May 2023 ➔ Aug 2023
Trial completion date • Trial initiation date • Trial primary completion date • Diabetic Neuropathy • Neuralgia • Pain • Renal Disease
November 03, 2022
A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetic Neuropathy • Neuralgia • Pain
October 03, 2022
A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Bayer
New P1 trial • Diabetic Neuropathy • Neuralgia • Pain
September 23, 2022
A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain
(clinicaltrials.gov)
- P2a | N=80 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain
August 26, 2022
Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants
(clinicaltrials.gov)
- P1 | N=63 | Completed | Sponsor: Bayer
New P1 trial • Endometriosis • Gynecology • Women's Health
June 06, 2022
A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Bayer
New P1 trial • Nephrology • Renal Disease
March 07, 2022
A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain
(clinicaltrials.gov)
- P2a | N=75 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain
1 to 11
Of
11
Go to page
1